Condition: ATTR Amyloidosis Wild Type · Sponsor: Steen Hvitfeldt Poulsen
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are: * What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt. * Safety of dobutamine infusion in this patient population. Participants will receive increasing doses of dobutamine infusion, and the effects on cardiac output and filling pressures will be assessed simultaneously by echocardiography and right heart catheterization.
This description comes directly from the study's public registry record.
Ali Hussein Jaber Mejren, MD · 0045 91 65 18 48 · alimej@clin.au.dk
Steen Hvitfeldt Poulsen, MD,PhD,DMSci · steepoul@rm.dk
Always discuss trial participation with your own doctor first.
| Department of Cardiology, Aarhus University Hospital | Aarhus, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06318260